Raxibacumab: a panacea for anthrax disease?

Lancet Infect Dis. 2020 Aug;20(8):886-887. doi: 10.1016/S1473-3099(20)30164-X. Epub 2020 Apr 22.

Authors

Michael H Norris¹, Jason K Blackburn²

Affiliations

¹ Spatial Epidemiology and Ecology Research Lab, Department of Geography, and Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA. Electronic address: mhnorris@ufl.edu.
² Spatial Epidemiology and Ecology Research Lab, Department of Geography, and Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA.

PMID: 32333846
DOI: 10.1016/S1473-3099(20)30164-X

No abstract available

MeSH terms

Animals
Anthrax / drug therapy*
Anthrax / microbiology
Anthrax Vaccines / immunology
Antibodies, Monoclonal, Humanized / immunology
Antibodies, Monoclonal, Humanized / therapeutic use*
Bacillus anthracis
Bacillus cereus
Humans
Immunologic Factors / immunology
Immunologic Factors / therapeutic use*

Substances

Anthrax Vaccines
Antibodies, Monoclonal, Humanized
Immunologic Factors
raxibacumab